326 chapter 4 Table 13. [18F]FDG-PET/CT parameters in nodules >10 mm (n=128) [18F]FDG-PET/CT-driven group diagnostic surgery group n (n = 89) (n = 39) p [18F]FDG-positive 128 65 (73%) 26 (67%) 0.47a Median SUVmax of the nodule, g/cm3 (IQR) 128 4.0 (2.8-10.7) 4.0 (2.5-8.3) 0.43b Median SUVpeak of the nodule, g/cm3 (IQR) 128 3.5 (2.3-8.4) 3.3 (2.1-6.1) 0.35b Median SUVmax of thyroid background, g/cm3 (IQR) 128 1.9 (1.7-2.4) 2.0 (1.7-2.5) 0.19b Median SUVmax ratio (IQR) 128 2.4 (1.4-6.2) 1.8 (1.1-4.1) 0.16b Median SUVpeak ratio (IQR) 128 1.9 (1.1-4.8) 1.5 (0.9-2.8) 0.11b IQR=interquartile range. SUV=standardized uptake value. a: Pearson’s chi-squared test. b: Mann-Whitney U test. Table 14. Therapeutic yield after one year of follow-up in nodules >10 mm (n=128) [18F]FDG-PET/CT-driven group (n=89) diagnostic surgery group (n=39) n % (95% CI) n % (95% CI) pa adjusted pb adjusted OR (95% CI)b Beneficial management 51 / 89 57% (46%-68%) 7 / 39 18% (8%-34%) <0.001a <0.001b 6.2 (2.4-16.1)b Surgery for malignant/borderline nodule 28 / 89 31% (22%-42%) 6 / 39 15% (6%-31%) 0.06a 0.09b 2.4 (0.9-6.8)b Surveillance for benign nodule 23 / 89 26% (17%-36%) 1 / 39 3% (0%-13%) 0.002a <0.001b 15.2 (1.9-120.2)b Unbeneficial management 38 / 89 43% (32%-54%) 32 / 39 82% (66%-92%) <0.001a <0.001b 0.2 (0.1-0.4)b Surgery for benign nodule 38 / 89 43% (32%-54%) 32 / 39 82% (66%-92%) <0.001a <0.001b 0.2 (0.1-0.4)b Surveillance for malignant/borderline nodule 0 / 89 0% (0%-4%) 0 / 39 0% (0%-9%) n.a. n.a. n.a. Avoided surgery in benign nodules 23 / 61 38% (26%-51%) 1 / 33 3% (0%-16%) <0.001a 0.003b 25.1 (3.0-211.6)b CI=confidence interval. n.a.=not applicable. OR=odds ratio. a: Pearson’s chi-squared test. b: binary logistic regression to adjust for stratifying variables.
RkJQdWJsaXNoZXIy MTk4NDMw